Pharming Group NV has entered into an exclusive distribution agreement with Cytobioteck S.A.S., a privately owned Bogota, Colombia based specialty healthcare company, for the distribution of RUCONEST® (recombinant human C1 inhibitor) for the treatment of acute attacks of HAE in Colombia and Venezuela.
Under the agreement, Cytobioteck will drive all regulatory processes and will purchase its commercial supplies of RUCONEST from Pharming at a fixed transfer price.
Sijmen de Vries, Pharming’s CEO commented: “We are very pleased that Cytobioteck will be engaged in the distribution of RUCONEST in Colombia and Venezuela, two countries where a considerable number of patients with HAE have been diagnosed.”
“This will be the key agreement to bring comfort and relief to patients with HAE in the region”, Cytobioteck’s CEO Osvaldo Piñeros commented. He also added “Our job is to deliver the best therapies available for our patients, and we will continue to do so with Pharming as a valuable and strategic ally.”
(Source: Pharming Group)